AB Studio is enhancing the potential and scalability of antibody-based therapeutics. There are many different types of antibodies that vary by target antigen, size and functionality. AB Studio is developing complex antibodies with enhanced efficacy, safety, and manufacturability features that have potential applications for treatment of cancer and infectious diseases. AB Studio depends upon computer-aided antibody design (CAAD) for therapeutic antibody discovery, lead selection, engineering, humanization and optimization. Antibodies made by AB Studio have been used in a variety of cases from developing tri-specific antibodies for COVID-19 to the creation of novel “imbalanced” bi-specific antibodies. 

<p>AB Studio is enhancing the potential and scalability of antibody-based therapeutics. There are many different types of antibodies that vary by target antigen, size and functionality. AB Studio is developing complex antibodies with enhanced efficacy, safety, and manufacturability features that have potential applications for treatment of cancer and infectious diseases. AB Studio depends upon computer-aided antibody design (CAAD) for therapeutic antibody discovery, lead selection, engineering, humanization and optimization. Antibodies made by AB Studio have been used in a variety of cases from developing tri-specific antibodies for COVID-19 to the creation of novel “imbalanced” bi-specific antibodies. </p>


Ab Studio

 AbbeyCross Emerging Market FX payments platform hits key milestone: Launch of ABX Studio with US Tier 1 Bank 

Candid Therapeutics Appoints Highly Accomplished Industry Leaders Angie You, Ph.D. and Dan Puckett to it’s Board of Directors

HIT launches Angelina Ballerina dance academy - Kidscreen

Candid Therapeutics Debuts with $370M Capital Raise to Clinically Evaluate Potentially Transformative Autoimmune Therapies


              Candid Therapeutics and Ab Studio Enter Into Research Collaboration to Discover and Develop Novel T Cell Engagers for Autoimmune Indications
            


              From the singularity community on Reddit: Google DeepMind's AlphaProteo generates novel proteins for biology and health research
            

Sarah Wilkinson: Menya uno mugeni yamaze imyaka 20 yegeranya uburyo kugira yirongore - BBC.com

Candid Therapeutics unwraps three new collaborations to discover and develop T-cell engager antibodies - Fierce Biotech

Candid Therapeutics to strengthen TCE pipeline through strategic collaborations - BioWorld Online

Angelina Ballerina Dance Program Comes to U.S. - License Global

Score hot deals on Black Friday! - SheKnows


              1272P - Updated results from a first-in-human, phase I/II study of GB263T, a novel EGFR/cMET/cMET tri-specific antibody, in patients with advanced EGFR-mutated (EGFRm) non-small cell lung cancer (NSCLC)
            

Click here for more information

ABS’ platforms on YouTube:

Computer designed humanized llama VHH library for antibody discovery webinar:
YouTube link: https://lnkd.in/gHEvicnp

Multi-specific therapeutic antibody design webinar:
Development of multi-specific therapeutic antibodies via computer aided design - YouTube

See you in Boston! 😊

Bride Sarah Wilkinson saves for 20 years to wed herself - BBC.com


              Candid Therapeutics Debuts with $370M Capital Raise to Clinically Evaluate Potentially Transformative Autoimmune Therapies
            

Felixstowe woman's wedded bliss one year after marrying herself - BBC.com

STUDIO 99 OPENS IN ROGERS PLACE OCTOBER 18 - Rogers Place

Candid Therapeutics and EpimAb Biotherapeutics Enter Into Research Collaboration to Discover and Develop Novel T-Cell Engagers for Autoimmune Indications


              Third Rock and Arie Belldegrun’s firm come together for CD20/CD3 bispecific out of China
            

See you at AET booth 602. 😄🤝

Many interesting talks from the 2024 mAbTalk symposium jointly organized by our society and Antibody Therapeutics! The theme of "AntibodyPlus: Bispecific Antibodies and Antibody-Drug Conjugates” highlights the innovations of the field. 
BIG thanks to all the great speakers of this event! Prof. Mitchell Ho （何苗壮）(Founding Editor-in-Chief of Antibody Therapeutics) reviewed the journey of our society's official journal, Antibody Therapeutics; Dr. Yue Liu from Ab Studio introduced the next generation of T cell engager technology; Dr. Stephen Demarest from Tentarix Biotherapeutics talked about the new multispecific assembly technology; Dr.Gerhard Frey from BioAtla, Inc. introduced their conditional ADC platform; Dr. Jianzhong Wen from Merck talked about how to use QSP models to guide ADC design and selection. 

#mab #mabs #antibody #antibodies #antibodyplus #bispecific #bsab #bsabs #bispecificantibody #bispecificantibodies #adc #adcs #antibodydrugconjugate #antibodydrugconjugates #antibodydiscovery #antibodydevelopment #biologics #symposium

We’d like to spotlight this excellent research article published in Antibody Therapeutics with the title of “A novel IgG Fc by computer-aided design enhances heavy-chain heterodimerization in bi- or trispecific antibodies”. The computationally designed novel ETYY mutations improve heterodimer formation in multi-specific antibodies while preserving the functional and physicochemical properties. This could greatly enhance the large-scale manufacturability and ease of purification for multi-specific antibodies for which heterodimerization is necessary. The corresponding author is Dr. Yue Liu at Ab Studio. The following picture was selected as cover picture of the issue. Open access to this paper at:
https://lnkd.in/eUXaj5aJ

Antibody Therapeutics is the official journal of Chinese Antibody Society, and is an international peer-reviewed, open access journal published by Oxford University Press. Antibody Therapeutics is indexed by ESCI, PubMed and Scopus (2023 CiteScore: 8.7). You are welcome to visit the official website of the journal (see link below) and submit your therapeutic antibody related manuscripts to our journal by June 30, 2025 to enjoy 50% APC (Article Processing Charge/publication fee) discount. 
https://lnkd.in/gsTu_U2

#antibodies #antibody #antibodytherapeutics #mabs #mab #antibodydiscovery #antibodydevelopment #biologics

Read our paper

Tiny prefab timber cabin in New Zealand designed to serene art studio - Inhabitat

Ab Studio

Business:

About: